Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial
bioRxiv (2020) - Comments
doi: 10.1101/2020.12.03.20238840 

Alben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt